BPC November 26 update

CCXI closes up 275% following data released Monday; Aravive ARAV offering

Price and Volume Movers

ChemoCentryx, Inc., (NASDAQ: CCXI) shares closed up 275% to $30.21 following news reported Monday that it met the primary endpoints in its Phase 3 ADVOCATE trial of avacopan, for the treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA-associated vasculitis or ANCA vasculitis). Shares had traded over $35 early in the session.

Proteostasis Therapeutics, Inc. (NASDAQ: PTI) shares closed up 27% to $2.40, with investors anticipating Phase 2 data from its cystic fibrosis trial due by the end of the year.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) shares closed up 19% to $67.70. Analysts at Piper Jaffray raised their price target from $54 to $72.

Aravive, Inc. (NASDAQ:ARAV) announced after hours it has commenced an underwritten public offering of the sale of its shares of common stock. Shares are currently trading down 13% to $8.15.

X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) shares closed down 17% to $11.03 following the pricing of its offering of 3,666,667 shares of its common stock and attached warrants to purchase shares of common stock, at a price of $12 per share and accompanying warrant for gross proceeds of $65m.


Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume


Baudax Bio, Inc. (BXRX): $6.86; +50%.

Hepion Pharmaceuticals, Inc. (HEPA): $4.62; +29%.

CymaBay Therapeutics, Inc. (CBAY): $1.66; +25%.

Neoleukin Therapeutics, Inc. (NLTX): $5.14; +21%.

Ardelyx, Inc. (ARDX): $7.54; +18%.


Tonix Pharmaceuticals Holding Corp. (TNXP): $1.05; -16%.

Kazia Therapeutics Limited (KZIA): $4.80; -14%.

Karuna Therapeutics, Inc. (KRTX): $72.88; -11%.

Amneal Pharmaceuticals, Inc. (AMRX): $3.04; -10%.

Fulcrum Therapeutics, Inc. (FULC): $13.52; -10%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

ACST – Acasti Pharma Inc.
CaPre (TRILOGY 1 and 2)

Phase 3 Phase 3 TRILOGY 1 data did not meet primary endpoint - January 13, 2020. TRILOGY 2 data due 3Q 2020.
$79.8 million

BVXV – BiondVax Pharmaceuticals Ltd.
Universal flu vaccine

Phase 2 Phase 2 data due 2Q 2020.
$198.7 million

CYTK – Cytokinetics Incorporated
Amyotrophic lateral sclerosis (ALS)

Phase 3 Phase 3 trial planned.
$1.2 billion

EVFM – Evofem Biosciences Inc.
Amphora - AMPOWER
contraceptive vaginal gel

Approved FDA Approval announced May 22, 2020.
$170 million

Elafibranor - RESOLVE-IT
Non-alcoholic steatohepatitis (NASH)

Phase 3 Phase 3 data did not meet primary endpoint - May 11, 2020.
$202 million